# Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers

> **NCT02256709** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 70 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBP 5371 CL tablet
- **DRUG:** BIBP 5371 CL solution
- **OTHER:** High fat, high caloric breakfast
- **DRUG:** Placebo tablet
- **DRUG:** BIBP 5371 CL tablet high dose
- **DRUG:** Placebo drinking solution
- **DRUG:** BIBP 5371 CL tablet low dose

## Key facts

- **NCT ID:** NCT02256709
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2004-08
- **Final completion:** —
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2014-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256709, "Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02256709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*